Cellares · Jun 2026
Cellares announced selection as one of seven companies in the FDA's inaugural Manufacturing PreCheck pilot, providing early regulatory engagement on facility design, quality systems, and manufacturing processes.
Company research
Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Overview
Cellares is a private biopharmaceutical manufacturing company and the first Integrated Development and Manufacturing Organization (IDMO). It combines automated cell-therapy manufacturing, quality control, process development, and global GMP manufacturing capacity to help academic, biotech, and pharmaceutical sponsors scale living medicines.
Primary product
Cell Shuttle™, an end-to-end, closed, automated cell-therapy manufacturing platform, complemented by Cell Q™ automated in-process and release quality control.
Founded
2019
Headquarters
345 Allerton Avenue, South San Francisco, California 94080, United States
Team size
200-300+
Industry
Pharmaceutical Manufacturing
Sub-industry
Cell and gene therapy manufacturing automation; contract development and manufacturing organization (CDMO/IDMO)
Offices
South San Francisco, California, United States
Bridgewater, New Jersey, United States
Leiden, Netherlands
Kashiwa City, Japan
Business model
B2B contract development and manufacturing services
Technology transfer and process-development services
Commercial manufacturing capacity reservation and supply agreements
Automated manufacturing platform and quality-control services
Funding
Stage
Series D / late-stage venture; generating revenue
Total raised
$682M
Latest round
Series D, including subsequent extensions · Jun 2026
Latest amount
$327M
Jun 2026 · Prime Radiant Partners
Jan 2026 · BlackRock and Eclipse
Aug 2023 · Koch Disruptive Technologies
May 2021 · Eclipse and Decheng Capital
Oct 2020 · Eclipse
People & investors
Leadership
Co-Founder and Chief Executive Officer
Co-Founder and President
Chief Operating Officer
Chief Financial Officer
Founders Chief of Staff and Vice President, Global Expansion
Former Senior Vice President, Engineering and Technology
Senior Director, Cell Therapy Operations
Founders
Co-Founder; former Chief Technology Officer
Work & culture
Public recruiting materials describe an interdisciplinary, mission-driven team focused on accelerating access to cell therapies and hiring engineers, scientists, operators, and manufacturing professionals. Independent employer-review signals indicate generally positive ratings, but detailed benefits and formal culture documentation were not publicly verified.
Compensation
Public job-market data shows indicative annual salaries of approximately $103,000 for Research Associate, $119,000 for Mechanical Engineer, and $162,000 for Senior Product Manager. These are third-party or aggregated signals rather than a complete company compensation framework; equity and benefits were not verified.
Product & market
Pricing
Custom enterprise pricing based on process development, technology transfer, manufacturing capacity, quality-control services, and long-term supply agreements; public list pricing was not found.
Differentiators
- —Integrated development, manufacturing, and quality-control service model rather than standalone equipment sales
- —Cell Shuttle is designed for closed, end-to-end automation of cell-therapy manufacturing
- —Cell Q adds automated in-process and release quality control
- —Company claims up to 10x more batches than conventional CDMO approaches with comparable footprint and headcount
- —Cell Shuttle received the FDA's Advanced Manufacturing Technology designation in April 2025
- —Cellares was selected for the FDA's inaugural Manufacturing PreCheck cohort in June 2026
- —Global Smart Factory network spanning the United States, Europe, and Japan
- —Commercial capacity agreements with major biopharmaceutical companies, including a potential $380 million Bristol Myers Squibb agreement
Technology
Cell Shuttle™ automated end-to-end cell-therapy manufacturing
Cell Q™ automated in-process and release quality control
Closed-system single-use manufacturing
Robotics and industrial automation
Industry 4.0 smart-factory architecture
Digital process transfer and manufacturing data systems
GMP manufacturing and automated analytical testing
Customers
Bristol Myers Squibb
Cabaletta Bio
TScan Therapeutics
ProTgen
Autolus Therapeutics
Sonoma Biotherapeutics
Lyell Immunopharma
University of Wisconsin School of Medicine and Public Health
Competitors
Ori Biotech
Multiply Labs
Cellular Origins
CellBri
CellQuest
Lonza
AGC Biologics
KBI Biopharma
Minaris Advanced Therapies
Scale & contact
Estimated revenue
$1 million-$10 million annually; one third-party estimate is approximately $4.5 million
Estimated monthly visits
19.6K
Traffic estimate as of Jun 2026
Latest news
Cellares · Jun 2026
A $50 million Prime Radiant investment expanded the Series D to $327 million. Cellares said the financing supports commercial-scale operations and European expansion.
Cellares · Apr 2026
Cellares and Cabaletta Bio entered a 10-year agreement for automated manufacture of rese-cel, potentially supporting thousands of batches per year pending regulatory approval.
Cellares · Apr 2026
The first two GMP doses manufactured on the Cell Shuttle met release specifications, were delivered on time, and were infused into patients in Cabaletta's clinical program.
Cellares · Jan 2026
Cellares announced an initial $257 million Series D co-led by BlackRock and Eclipse, bringing the company's stated total capital raised at that point to $612 million and funding global Smart Factory expansion.
Jobs and careers at Cellares
0 jobs at Cellares
No open positions
Check back later for new openings